Search for: [Abstract = "ocess among EU\-CEE countries i.e., Bulgaria, Croatia, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, and Slovakia revealed that some of the considered countries already established separate regulations on reimbursement of orphan drugs\; in case of some of these countries higher ICER values for orphans are used\; in Lithuania and Romania, no formal HTA process was employed. The examination of orphan drugs in selected countries showed that the share of reimbursed orphan drugs varied significantly across the countries, but it was not associated either with GDP or GDP per capita. Analysis of agreement in decision\-making regarding reimbursement of orphan drugs revealed that the lowest, slight agreement in reimbursement decisions was observed between Estonia and Latvia, and the highest, substantial agreement, between Estonia and Lithuania. Additionally, in Czechia, Lithuania and Slovakia, EMA’s conditional approval significantly decreased the chances for reimbursement. What is more, in Croatia, Estonia, Hungary, and Lithuania, drugs for oncological diseases had significantly greater chances for reimbursement. Detailed analysis of HTA recommendation\-making process revealed that in Hungary, Latvia, and Slovakia, a positive recommendation was associated with a positive reimbursement decision, while a negative recommendation, with a lack of reimbursement. The study of"]

Number of results: 1